Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Lenalidomide and chronic lymphocytic leukemiaImmune reconstitution in chronic lymphocytic leukemiaImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaChronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Hepatitis B and hepatitis C viral infections in patients with chronic lymphocytic leukemiaOutcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemiaLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.Expanding role of lenalidomide in hematologic malignanciesState-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.Lenalidomide in the treatment of chronic lymphocytic leukemia.Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.Initial treatment of CLL: integrating biology and functional status.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia.Targeting inflammatory pathways in chronic lymphocytic leukemia.Personalized medicine in CLL: current status and future perspectives.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.Front-line therapy for chronic lymphocytic leukemia.Lenalidomide alone and in combination for chronic lymphocytic leukemia.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.New treatment options for chronic lymphocytic leukemia.Promising therapies for the treatment of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.
P2860
Q26768154-F9B5EDA8-EF7A-4E9F-9C4D-2265FACE4E8BQ26823597-40954167-5FA6-4C67-AE8C-744C6613F9A7Q26865561-CF063FD5-F134-4772-BB14-09A32F95127CQ27001318-525904A8-DAE5-45FB-ACE6-F6CE4AF75379Q30538420-BE3106FB-1AF6-4E1C-921C-B8DE84E8D0DAQ31056968-A74BE477-230E-4143-A3D8-85DEA02B7502Q33406478-C8148D16-B9CD-4982-8B61-6A1BB4AE19BDQ33417117-0E6E5CE2-5111-47E4-BBB4-7D28CA2F9A96Q33418964-1A5184A8-7A48-4607-8054-6F745FCE18C7Q33796183-09BF1D49-64A2-4CA7-A29C-574326D62EF9Q33810030-AA634AB7-2EE3-4075-9958-A6311F01AB9AQ33978930-56685A76-4AD8-44D7-8B96-4381AF65F514Q34008584-06729CE9-916F-4BC5-B949-4F3C470B5D7AQ34009041-7D4BFFF1-C8A2-4C39-BB9A-2D31E49B8B1CQ34052075-6BF93A3A-7F47-4CCC-A811-8970AF2E91BAQ34172063-5E261F0D-818E-48AC-99C2-AC7ECB5D54F3Q34440110-DC985733-C9C0-415F-AF54-E8CF1A7E35EFQ34625543-3126FF25-6C0E-4027-85EC-37C1E4D4E9AEQ35011166-0C289CDD-76BA-4D3E-B307-6F4E25A1A764Q35592305-DCE369A5-272E-4D30-BEFE-033723FFADD2Q35860550-ECAD0AE8-933E-439D-975C-11E447B5E118Q36010202-E45FDE93-F626-4CD6-838E-A9AB87748570Q36125070-A7FA3497-BA0A-4B79-AAC7-8EB6B73D2A3AQ36177909-1FE8F482-6568-422D-B3C2-7D4BDF6C66F1Q36219647-19B45D5B-DBDC-4328-BA5D-C34D7FB15004Q36715966-49EB271B-B881-4285-AE07-FCFE0EF603CFQ36739295-94FBCE66-25D3-44A3-999A-3A6D0FD292C9Q36929831-17810321-68CC-4920-804F-04977012CF57Q37147789-D84F5B5E-7C25-4157-B189-72FC2FEB3ED8Q37351312-6EAB833C-8AE1-4404-8F2B-A6DA86E8821AQ37412148-7D71D78D-7488-411C-AFAE-ABFBFE644E07Q37605306-78365F08-9233-4458-90D2-02FE35AE6072Q37610087-8516E27A-C7AB-4B90-A376-BB7FA346CA55Q37958036-2846BE09-67DC-44DB-80DA-FB781E8226D4Q37964914-6AB23110-647B-493D-82B3-3DEE41B7F248Q38068736-7177D9AF-8583-4C6E-81AE-E1C82BADFAFCQ38155343-4CA24749-E5B1-40E7-A9E5-16AA9F14E713Q38190095-AA0ED53F-6AC5-4AE4-89E4-453D79A899EAQ38366441-F8672A6D-9607-4B59-863F-03291DE4A4BFQ38543771-533DDA8B-555B-489C-BD32-23DC3C862793
P2860
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Single-agent lenalidomide in t ...... chronic lymphocytic leukemia.
@en
type
label
Single-agent lenalidomide in t ...... chronic lymphocytic leukemia.
@en
prefLabel
Single-agent lenalidomide in t ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P356
P1476
Single-agent lenalidomide in t ...... d chronic lymphocytic leukemia
@en
P2093
Anthea Lau
Christine I Chen
Chungyee Leung-Hagesteijn
David Spaner
Harminder Paul
James Johnston
Joseph Brandwein
Mariela Pantoja
Nimisha Dave
P2860
P304
P356
10.1200/JCO.2010.29.8133
P407
P577
2010-12-28T00:00:00Z